Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
300 participants
OBSERVATIONAL
2022-05-19
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Effectiveness of AF Analysis Software in AF Rhythm Monitoring
NCT05333380
Study of Atrial Fibrillation Combined with Atrial Functional Mitral Regurgitation
NCT06630936
Predicting Development of SCAF in Device Patients
NCT02808260
Symptom Preoccupation in Atrial Fibrillation (AF) and Its Role in AF-related Disability
NCT04123327
Investigation of Specific Biomarkers in Patients With Atrial Fibrillation Who Undergo Interventional Treatment
NCT05170607
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging
ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed Informed Consent
Exclusion Criteria
* Moderate to severe renal impairment (eGFR \< 30)
* Active gastrointestinal bleeding
* Active infection or fever
* Short life expectancy
* Significant anaemia
* Severe uncontrolled systemic hypertension
* Severe electrolyte imbalance
* Congestive heart failure - NYHA Class IV
* Recent myocardial infarction
* Bleeding or clotting disorders
* Uncontrolled diabetes
* Inability to receive IV or oral Anticoagulants
* Unable to give informed consent
* Pregnancy
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imperial College Healthcare NHS Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21HH7349
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.